Alpha Tau Expands Pancreatic Cancer Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy DRTS?
Source: Newsfilter
- Trial Size Expansion: The FDA's approval of Alpha Tau's IDE supplement increases the total patient count for the pancreatic cancer trial from 30 to 40, indicating the company's proactive approach in developing new therapies to meet high patient needs.
- New Treatment Exploration: The trial will evaluate the safety and efficacy of combining Alpha DaRT with standard chemotherapy agents gemcitabine/nab-paclitaxel in newly diagnosed patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma, potentially offering new treatment options for patients.
- Patient Recruitment Plan: Recruitment for the 40 patients is now expected to conclude in Q3 2026, despite earlier plans for Q2 completion, reflecting the company's adaptability in clinical research amid dependencies on clinical site approvals.
- Clear Clinical Objectives: The primary goals of the IMPACT study include assessing the feasibility of Alpha DaRT source implantation and monitoring for serious adverse events related to the device, further advancing Alpha Tau's strategic development in cancer treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DRTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DRTS
Wall Street analysts forecast DRTS stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.080
Low
5.00
Averages
7.00
High
9.00
Current: 8.080
Low
5.00
Averages
7.00
High
9.00
About DRTS
Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Launch of ACAPELLA Clinical Trial for LAPC
- First Patient Treatment: The successful treatment of the first patient in the ACAPELLA trial at CHU Grenoble Alpes marks the first use of Alpha DaRT for pancreatic cancer in Europe, potentially introducing new treatment options in this critical area.
- Patient Population Size: With approximately 140,000 Europeans diagnosed with pancreatic cancer annually, and 30% presenting with locally advanced inoperable disease, the ACAPELLA trial aims to provide a new treatment pathway for these patients, addressing a significant unmet need.
- Clinical Trial Design: The ACAPELLA trial plans to enroll up to 40 patients to evaluate the safety of Alpha DaRT in combination with capecitabine, with the primary endpoint being the incidence of device-related serious adverse events, which holds substantial clinical significance.
- Global Strategic Expansion: This trial is a key component of Alpha Tau's clinical expansion strategy in Europe, alongside the ongoing IMPACT trial in the U.S., demonstrating the company's commitment to innovation in pancreatic cancer treatment.
See More
Alpha Tau Expands Pancreatic Cancer Clinical Trial
- Trial Size Expansion: The FDA's approval of Alpha Tau's IDE supplement increases the total patient count for the pancreatic cancer trial from 30 to 40, indicating the company's proactive approach in developing new therapies to meet high patient needs.
- New Treatment Exploration: The trial will evaluate the safety and efficacy of combining Alpha DaRT with standard chemotherapy agents gemcitabine/nab-paclitaxel in newly diagnosed patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma, potentially offering new treatment options for patients.
- Patient Recruitment Plan: Recruitment for the 40 patients is now expected to conclude in Q3 2026, despite earlier plans for Q2 completion, reflecting the company's adaptability in clinical research amid dependencies on clinical site approvals.
- Clear Clinical Objectives: The primary goals of the IMPACT study include assessing the feasibility of Alpha DaRT source implantation and monitoring for serious adverse events related to the device, further advancing Alpha Tau's strategic development in cancer treatment.
See More
Alpha Tau Medical to Present Clinical Trial Results at DDW 2026
- Clinical Trial Results: Alpha Tau Medical announced that results from two clinical trials in Jerusalem for pancreatic cancer have been accepted for oral presentation at DDW 2026, marking the first major showcase of its Alpha DaRT technology in this field, potentially enhancing the company's reputation and market recognition in cancer treatment.
- Significant Conference Presentation: The presentation is scheduled for May 2, 2026, during the Pancreatic Cancer Diagnosis and Treatment session at DDW 2026, led by Dr. Harold Jacob from Hadassah Medical Center, which is expected to attract attention from numerous industry experts and further promote the clinical application of Alpha DaRT.
- Recognition of Technological Potential: CEO Uzi Sofer stated that this achievement reflects the growing recognition of the potential of their technology, especially given that most pancreatic cancer patients are deemed inoperable at diagnosis, with Alpha DaRT offering new treatment hope that could change patient outcomes.
- Future Research Directions: Chief Medical Officer Dr. Robert Den emphasized that these foundational studies have provided critical insights for their clinical development program, including the ongoing IMPACT pilot study actively enrolling in the U.S., demonstrating the company's commitment to advancing the commercialization of Alpha DaRT technology.
See More
Alpha Tau Medical Advances Clinical Trials for Cancer Treatments
- IMPACT Trial Overview: Alpha Tau's IMPACT trial is set to enroll up to 30 patients with newly diagnosed, inoperable pancreatic adenocarcinoma across the U.S., Canada, and Israel, with patient enrollment expected to complete by Q1 2026, aiming to evaluate the safety and effectiveness of Alpha DaRT, potentially offering new treatment options for patients.
- ReSTART Trial Focus: The ongoing ReSTART study evaluates Alpha DaRT in patients with recurrent cutaneous squamous cell carcinoma, also expected to complete enrollment by Q1 2026, particularly targeting patients ineligible for surgery or standard radiation, highlighting significant market demand for this therapy.
- FDA Certification Progress: Alpha Tau has secured Breakthrough Device Designation from the U.S. FDA for recurrent cutaneous squamous cell carcinoma and other cancers, reflecting high regulatory recognition of the therapy's potential, which may accelerate its review and development process, enhancing market competitiveness.
- Market Sentiment Analysis: DRTS stock has maintained a 'bullish' sentiment on Stocktwits over the past 24 hours, with a year-to-date gain of nearly 38%, indicating strong investor expectations for upcoming clinical trial data that could further drive stock price appreciation.
See More
Alpha Tau Medical Reports FY GAAP EPS of -$0.42
- Earnings Report: Alpha Tau Medical reported a FY GAAP EPS of -$0.42, indicating challenges in profitability that may negatively impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents, short-term deposits, and restricted deposits totaling $76.9 million, an increase from $62.9 million at December 31, 2024, suggesting improved liquidity management.
- Future Outlook: Updates on pancreatic cancer and GBM indicate that Alpha Tau Medical is positioning itself for a strong and catalyst-rich 2026, potentially attracting more investor interest.
- Market Reaction: Despite the reported losses, the company's efforts in R&D and market expansion may yield positive market reactions in the future, particularly with new therapies and clinical trial advancements.
See More
Japan Approves New Head and Neck Cancer Treatment Device
- Innovative Treatment Device: HekaBio K.K. announces that its developed Alpha DaRT (Diffusing Alpha Radiation Therapy) device has received official approval in Japan, becoming the first country outside Israel to approve it, marking Japan's leadership in tumor treatment.
- Significant Market Potential: Designed for patients with unresectable locally advanced or recurrent head and neck cancer, this device offers a new therapeutic option, expected to significantly improve treatment outcomes and fill the gap left by conventional therapies.
- Clinical Trial Results: Clinical trials demonstrate that Alpha DaRT effectively disrupts tumor cell DNA, leading to cell death, with high safety and efficacy, providing crucial evidence for future clinical applications and potentially transforming head and neck cancer treatment.
- Strategic Collaboration and Development: HekaBio is closely collaborating with Japanese medical professionals to conduct post-marketing studies and explore reimbursement options for Alpha DaRT, indicating its long-term growth potential in the Japanese market and commitment to patients.
See More
Launch of ACAPELLA Clinical Trial for LAPC
- First Patient Treatment: The successful treatment of the first patient in the ACAPELLA trial at CHU Grenoble Alpes marks the first use of Alpha DaRT for pancreatic cancer in Europe, potentially introducing new treatment options in this critical area.
- Patient Population Size: With approximately 140,000 Europeans diagnosed with pancreatic cancer annually, and 30% presenting with locally advanced inoperable disease, the ACAPELLA trial aims to provide a new treatment pathway for these patients, addressing a significant unmet need.
- Clinical Trial Design: The ACAPELLA trial plans to enroll up to 40 patients to evaluate the safety of Alpha DaRT in combination with capecitabine, with the primary endpoint being the incidence of device-related serious adverse events, which holds substantial clinical significance.
- Global Strategic Expansion: This trial is a key component of Alpha Tau's clinical expansion strategy in Europe, alongside the ongoing IMPACT trial in the U.S., demonstrating the company's commitment to innovation in pancreatic cancer treatment.
See More
Alpha Tau Expands Pancreatic Cancer Clinical Trial
- Trial Size Expansion: The FDA's approval of Alpha Tau's IDE supplement increases the total patient count for the pancreatic cancer trial from 30 to 40, indicating the company's proactive approach in developing new therapies to meet high patient needs.
- New Treatment Exploration: The trial will evaluate the safety and efficacy of combining Alpha DaRT with standard chemotherapy agents gemcitabine/nab-paclitaxel in newly diagnosed patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma, potentially offering new treatment options for patients.
- Patient Recruitment Plan: Recruitment for the 40 patients is now expected to conclude in Q3 2026, despite earlier plans for Q2 completion, reflecting the company's adaptability in clinical research amid dependencies on clinical site approvals.
- Clear Clinical Objectives: The primary goals of the IMPACT study include assessing the feasibility of Alpha DaRT source implantation and monitoring for serious adverse events related to the device, further advancing Alpha Tau's strategic development in cancer treatment.
See More
Alpha Tau Medical to Present Clinical Trial Results at DDW 2026
- Clinical Trial Results: Alpha Tau Medical announced that results from two clinical trials in Jerusalem for pancreatic cancer have been accepted for oral presentation at DDW 2026, marking the first major showcase of its Alpha DaRT technology in this field, potentially enhancing the company's reputation and market recognition in cancer treatment.
- Significant Conference Presentation: The presentation is scheduled for May 2, 2026, during the Pancreatic Cancer Diagnosis and Treatment session at DDW 2026, led by Dr. Harold Jacob from Hadassah Medical Center, which is expected to attract attention from numerous industry experts and further promote the clinical application of Alpha DaRT.
- Recognition of Technological Potential: CEO Uzi Sofer stated that this achievement reflects the growing recognition of the potential of their technology, especially given that most pancreatic cancer patients are deemed inoperable at diagnosis, with Alpha DaRT offering new treatment hope that could change patient outcomes.
- Future Research Directions: Chief Medical Officer Dr. Robert Den emphasized that these foundational studies have provided critical insights for their clinical development program, including the ongoing IMPACT pilot study actively enrolling in the U.S., demonstrating the company's commitment to advancing the commercialization of Alpha DaRT technology.
See More
Alpha Tau Medical Advances Clinical Trials for Cancer Treatments
- IMPACT Trial Overview: Alpha Tau's IMPACT trial is set to enroll up to 30 patients with newly diagnosed, inoperable pancreatic adenocarcinoma across the U.S., Canada, and Israel, with patient enrollment expected to complete by Q1 2026, aiming to evaluate the safety and effectiveness of Alpha DaRT, potentially offering new treatment options for patients.
- ReSTART Trial Focus: The ongoing ReSTART study evaluates Alpha DaRT in patients with recurrent cutaneous squamous cell carcinoma, also expected to complete enrollment by Q1 2026, particularly targeting patients ineligible for surgery or standard radiation, highlighting significant market demand for this therapy.
- FDA Certification Progress: Alpha Tau has secured Breakthrough Device Designation from the U.S. FDA for recurrent cutaneous squamous cell carcinoma and other cancers, reflecting high regulatory recognition of the therapy's potential, which may accelerate its review and development process, enhancing market competitiveness.
- Market Sentiment Analysis: DRTS stock has maintained a 'bullish' sentiment on Stocktwits over the past 24 hours, with a year-to-date gain of nearly 38%, indicating strong investor expectations for upcoming clinical trial data that could further drive stock price appreciation.
See More
Alpha Tau Medical Reports FY GAAP EPS of -$0.42
- Earnings Report: Alpha Tau Medical reported a FY GAAP EPS of -$0.42, indicating challenges in profitability that may negatively impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents, short-term deposits, and restricted deposits totaling $76.9 million, an increase from $62.9 million at December 31, 2024, suggesting improved liquidity management.
- Future Outlook: Updates on pancreatic cancer and GBM indicate that Alpha Tau Medical is positioning itself for a strong and catalyst-rich 2026, potentially attracting more investor interest.
- Market Reaction: Despite the reported losses, the company's efforts in R&D and market expansion may yield positive market reactions in the future, particularly with new therapies and clinical trial advancements.
See More
Japan Approves New Head and Neck Cancer Treatment Device
- Innovative Treatment Device: HekaBio K.K. announces that its developed Alpha DaRT (Diffusing Alpha Radiation Therapy) device has received official approval in Japan, becoming the first country outside Israel to approve it, marking Japan's leadership in tumor treatment.
- Significant Market Potential: Designed for patients with unresectable locally advanced or recurrent head and neck cancer, this device offers a new therapeutic option, expected to significantly improve treatment outcomes and fill the gap left by conventional therapies.
- Clinical Trial Results: Clinical trials demonstrate that Alpha DaRT effectively disrupts tumor cell DNA, leading to cell death, with high safety and efficacy, providing crucial evidence for future clinical applications and potentially transforming head and neck cancer treatment.
- Strategic Collaboration and Development: HekaBio is closely collaborating with Japanese medical professionals to conduct post-marketing studies and explore reimbursement options for Alpha DaRT, indicating its long-term growth potential in the Japanese market and commitment to patients.
See More
